US › Healthcare

Aligos Therapeutics Inc (ALGS)

US · Healthcare · Biotechnology

$4.75+3.26%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$2.8M

Revenue YoY

+810.0%

Net profit

$-23.0M

Profit YoY

-153.5%

EPS

$-2.21

EPS estimate

$-2.37

Net margin

-814.1%

EPS came in at -2.21 against a street estimate of -2.37 — a beat of 6.8%.

Key statistics

Market cap

$28.5M

Forward P/E

0.0

P/B

0.82

Book value

$5.14

EPS (TTM)

$-9.78

52-week high

$13.69

52-week low

$3.98

50-day MA

$5.40

200-day MA

$7.39

Beta

2.28

Analyst view

Analysts rate Aligos Therapeutics Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $56.29.

Shareholding

Insiders

10.76%

Institutions

55.09%

Largest institutional holders

Fund	Stake
Deep Track Capital, LP	7.18%
Alyeska Investment Group, L.P.	6.66%
Sio Capital Management, LLC	5.29%
Marshall Wace Asset Management Ltd	4.32%
Bank of America Corp	3.71%
Vanguard Capital Management, LLC	2.88%
Woodline Partners LP	2.87%
SummitTX Capital, L.P	2.40%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Aligos Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.